Previous 10 | Next 10 |
Karyopharm to Participate at Barclays Global Healthcare Conference PR Newswire NEWTON, Mass. , March 8, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least...
Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q4 2022 Earnings Call Feb 15, 2023 , 8:00 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q4 2022 Earnings Call Transcript
Karyopharm Therapeutics, Inc. (KPTI) Q4 2022 Earnings Conference Call February 15, 2023, 08:00 ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Reshma Rangwala - Chief Me...
Karyopharm Therapeutics press release ( NASDAQ: KPTI ): Q4 GAAP EPS of -$0.43 misses by $0.09 . Revenue of $33.6M (-73.4% Y/Y) misses by $0.14M . Cash, cash equivalents, restricted cash and investments as of December 31, 2022 totaled $279.7 million, compared to $235.6 ...
Karyopharm Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress PR Newswire -- Total Revenue of $157.1 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $120.4 Million for Full Year 2022, Meeting Company's Gu...
Karyopharm Therapeutics ( NASDAQ: KPTI ) is scheduled to announce Q4 earnings results on Wednesday, February 15th, before market open. The consensus EPS Estimate is -$0.36 (vs. $0.46 last year) and the consensus Revenue Estimate is $33.74M (vs. $126.2M last year). Over the las...
Karyopharm to Present at SVB Securities Global Biopharma Conference PR Newswire NEWTON, Mass. , Feb. 9, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced ...
Karyopharm to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 PR Newswire -- Conference Call Scheduled for Wednesday, February 15, 2023 , at 8:00 a.m. ET -- NEWTON, Mass. , Feb. 8, 2023 /PRNewswire/ -- Karyopharm Th...
Karyopharm Therapeutics ( NASDAQ: KPTI ) added ~5% pre-market Thursday after Piper Sandler launched its coverage with an Overweight recommendation citing the potential of the company’s FDA-approved cancer therapy Xpovio. The treatment is currently indicated with dexamethaso...
News, Short Squeeze, Breakout and More Instantly...
Karyopharm Therapeutics Inc. Company Name:
KPTI Stock Symbol:
NASDAQ Market:
Karyopharm Therapeutics Inc. Website:
Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 PR Newswire -- Conference Call Scheduled for Tuesday, August 6, 2024 , at 8:00 a.m. ET -- NEWTON, Mass. , July 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasd...
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates PR Newswire Long-Term Follow-Up Data Signal Promising Progression-Free S...
Karyopharm to Participate at the Jefferies Global Healthcare Conference PR Newswire NEWTON, Mass. , May 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announ...